Kurs
+1,52%
Likviditet
169 MDKK
Kalender
| Est. tid* | ||
| 2026-03-30 | N/A | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2026-02-19 | - | Bokslutskommuniké 2025 |
| 2025-11-13 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-14 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-03-28 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2025-03-27 | - | Årsstämma |
| 2025-02-20 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2024-03-20 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2023-03-29 | - | Årsstämma |
| 2023-03-02 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-09 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2022-04-06 | - | Årsstämma |
| 2022-03-10 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2021-04-15 | - | Årsstämma |
| 2021-03-11 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-03 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2020-04-02 | - | Årsstämma |
| 2020-03-12 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-05 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2019-04-04 | - | Årsstämma |
| 2019-03-07 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2018-04-19 | - | Årsstämma |
| 2018-03-07 | - | Bokslutskommuniké 2017 |
| 2017-11-08 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-06 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2017-04-05 | - | Årsstämma |
| 2017-03-15 | - | Bokslutskommuniké 2016 |
| 2016-11-09 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-18 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-20 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2016-04-19 | - | Årsstämma |
| 2016-03-16 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-22 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2015-04-21 | - | Årsstämma |
| 2015-03-12 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | Kapitalmarknadsdag 2014 |
| 2014-04-29 | - | Årsstämma |
| 2014-04-29 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2014-03-20 | - | Bokslutskommuniké 2013 |
| 2013-11-15 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-29 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-15 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-30 | - | Årsstämma |
| 2013-04-30 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2013-03-14 | - | Bokslutskommuniké 2012 |
| 2012-11-29 | - | Kapitalmarknadsdag 2012 |
| 2012-04-26 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2012-04-25 | - | Årsstämma |
| 2011-11-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-10-25 | - | Kapitalmarknadsdag 2011 |
| 2011-08-18 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-29 | - | X-dag ordinarie utdelning ZEAL 0.00 DKK |
| 2011-04-28 | - | Årsstämma |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Press release – No. 5 / 2026
Zealand Pharma to participate in upcoming investor conferences in March 2026
Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026.
- 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami
Adam Steensberg, President and Chief Executive Officer, will host investor meetings on Tuesday, March 10.
- Barclays 28th Annual Global Healthcare Conference, March 10-12 in Miami
Adam Steensberg, President and Chief Executive Officer, will host investor meetings on Wednesday, March 11 and participate in a fireside chat at 2:00pm EDT (7:00pm CET)
A live audio webcast of the fireside chat will be available at Zealand Pharma - 1755610, and accessible through the company’s website at https://www.zealandpharma.com/investors/events-presentations/, where a recording of the webcast will also be archived after the event.
- DNB Carnegie Healthcare Conference, March 10-12 in Stockholm
Henriette Wennicke, Chief Financial Officer, will host investor meetings on Thursday, March 12.
- BNP Paribas 2026 Healthcare Conference, March 24 in London
Adam Steensberg, President and Chief Executive Officer, will host investor meetings on Tuesday, March 24.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.
To date, more than 10 Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: alange@zealandpharma.com
Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
Email: RJamesOwens@zealandpharma.com